Taysha Gene Therapies finalizes separation with ex-CEO, includes RSU award and board resignation

Taysha Gene Therapies, Inc.

Ex-CEO R.A. Session II resigned from operating role on Dec 16, 2022; severance agreement finalized March 7, 2023.
Severance includes salary continuation for 12 months at his base salary as of separation date.
Also includes COBRA premium payments until Dec 31, 2023 or earlier if new coverage.
Compensation Committee awarded 251,296 vested RSUs replacing a canceled option of 199,500 shares for 2021 performance bonus.
Session also resigned from Board on March 2, 2023, not due to any disagreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

R.A. Session II

President and Chief Executive Officer

TSHA · Taysha Gene Therapies, Inc.

Effective: 2022-12-16
Filed: March 8, 2023, 6:59 PM ET

On December 16, 2022 (the “ Separation Date ”), R.A. Session II, the former President and Chief Executive Officer of the Company, resigned from his operating role, effective immediately.

Departed

R.A. Session II

Director

TSHA · Taysha Gene Therapies, Inc.

Effective: 2023-03-02
Filed: March 8, 2023, 6:59 PM ET

On March 2, 2023, Mr. Session notified the Board of his resignation from the Board and all committees thereof effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

R.A. Session II resigned as President and Chief Executive Officer at Taysha Gene Therapies, Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

On December 16, 2022 (the “ Separation Date ”), R.A. Session II, the former President and Chief Executive Officer of the Company, resigned from his operating role, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

R.A. Session II resigned as Director at Taysha Gene Therapies, Inc..

Action: resigned
Role: Director

Exact text from the filing

On March 2, 2023, Mr. Session notified the Board of his resignation from the Board and all committees thereof effective immediately.

View on SEC.gov

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-064669

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.